 |
||||||||||||||
|
 |
May 14th, 2007 2006 Annual Report - Excellent Results and Future Investments Octapharma AG has just released its latest annual report documenting the company’s remarkable results for 2006. The growth and financial robustness demonstrated over the past year has enabled Octapharma to move forward with significant investments to ensure the future success of the company.
In 2006, Octapharma met its long-term goal of achieving profits equivalent to 20% of revenues. For the company, this figure is seen as a prerequisite for meeting its commitments to maintain a continuous supply of high quality pharmaceutical products.
New Mission Since its foundation in 1983, Octapharma has been focused on developing high quality, virus safe pharmaceutical products based on human plasma. Over the past ten years Octapharma has also invested in recombinant technologies for the manufacture of bio-engineered proteins. In 2007 further significant investments are planned to meet the challenges associated with up-scale manufacture, clinical studies and regulatory submissions. The growing success in the area of recombinant technology has motivated Octapharma to revise its mission statement – for the safe and optimal use of plasma. As of 2007 this has become “for the safe and optimal use of human proteins” a statement that better reflects the company’s growing and diversified portfolio including both human plasma -derived and recombinant products. © Octapharma AG, 2007 |
